rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Drug safety
    sub title: progress and controversies : proceedings of the IVth International Congress of Pharmaceutical Physicians = Sécurité et médicament : progrès et controverses : comptes rendus du IVe congrès international des médecins de l'industrie pharmaceutique
  title info:
    title: Sécurite et médicament
  name:
    name part: International Congress of Pharmaceutical Physicians 1981 : Paris, France)
    role:
      role term: creator
  name:
    name part: Auriche, Michel
    role:
      role term: editor.
  name:
    name part: Burke, John McDonald
    role:
      role term: editor.
  name:
    name part: Duchier, Jacques
    role:
      role term: editor.
  name:
    name part: ScienceDirect (Online service)
  type of resource: text
  genre: conference publication
  genre: Electronic books.
  genre: Congress
  genre: proceedings (reports)
  genre: Conference papers and proceedings
  genre: Conference papers and proceedings.
  genre: Actes de congrès.
  origin info:
    place:
      place term: fr
    date issued: 1982
    issuance: monographic
  language:
    language term: eng
  language:
    language term: fre
  physical description:
    form: remote
    extent: 1 online resource (xviii, 308 pages) : illustrations
  table of contents: Front Cover; Copyright Page; Drug Safety: Progress and Controversies; Table of Contents; PREFACE; ALLOCUTION DE BIENVENUE; Introduction; PART I: DRUG SAFETY: A MULTIFACETED PROBLEM DIVERSITE DES PROBLEMES POSES PAR L'EVALUATION DE LA SECURITE ENMATIERE DE MEDICAAIENTS; Chapter 1. The Scientific Basis of Drug Safety Regulations; HOW CAN DRUG SAFETY BE REGULATED?; DO DRUG SAFETY REQUIREMENTS IMPEDE DRUG INNOVATION?; WHAT IS THE SIGNIFICANCE OF THE BENEFIT-TO-RISR RATIO?; WHERE ARE THE LIMITS OF SAFETY REGULATIONS?; CAN CLINICAL TRIALS BE EXPEDITED WITHOUT NEGLECTING DRUG SAFETY?
  table of contents: HOW CAN THE SCIENTIFIC BASIS OF DRUG SAFETY BE IMPROVED?REFERENCES; Chapter 2. The Effects of Drug Regulation on Iatrogenic Disease; Abstract; A FOLLOW-UP STUDY OF REJECTIONS; A RETROSPECTIVE STUDY OF RESTRICTIVE DECISIONS; MAJOR IATROGENIC ACCIDENTS IN RETROSPECT; EFFICIENCY OF REGULATORY ACTIVITY ON SAFETY MATTERS; OTHER TECHNIQUES; AN INVALID TECHNIQUE; CONCLUSIONS; REFERENCES; Chapter 3. Deregulation of Drug Development: If Effective, Can it be Safe?; Abstract; THE EARLY STAGES : LESS-STHINGENT CONTROL; SEQUENTIAL SUBMISSION AND REVIEW; REALISTIC STANDARDS OF EVIDENCE FOR EFFICACY.
  table of contents: ACCEPTANCE OF FOREIGN AND IRREGULAR DATAIMPROVED ADMINISTRATIVE AND MANAGEMENT TECHNIQUES; POSTMARKETING ISSUES; CONCLUSIONS; REFERENCES; Chapter 4. Les grainds médicaLinents d'hier auraient-ils franchi avec succes le bairrage de la réglementation préclinique actuelle?; Resume; LES COMMISSIONS D'AGREMENT; LE PRIX ET LA DURÉE DES ESSAIS PRÉCLINIQUES; LES LABORATOIRES DE RECHERCHE PHARMACEUTIQUE; QUELQUES DOSSIERS DE GRANDS MEDICAMENTS ANCIENS; CONCLUSIONS; REFERENCES; Chapter 5. The Intemationad Transfer of Information Regarding Drug Saifety : Benefits, Difficulties and Solutions; Abstract.
  table of contents: Chapter 6. Ethicad Considerations in Drug Saifety EvaduationAbstract; CONFLICT OF INTEREST IN RESEARCH; ETHICAL ISSUES IN CLINICAL DRUG TRIALS; THE MARKETING AND USE OF DRUGS; DRUGS IN T H E THIRD WORLD; THE CARE AND FEEDING OF PHARAiACEUTICAL PHYSICIANS; REFERENCES; Chapter 7. A Compairisoii of International Guidelines for the Clinicad Evaduation of Psychotropic Drugs The Price of Safety; Abstract; Chapter 8. USA et FDA Versus CEE et CSP Une etude comparative ouverte des medicaments anti-aingoreux; Resume.
  table of contents: PART II:POST MARKETING SAFETY ASSESSMENT INTERET ET LIMITES DES METHODES D'EVALUATION CLINIQUE DES EFFETS INDESIRABLES DES MEDICAMENTS APRES MISE SUR LE MARCHE: PRESENT METHODSChapter 9. Spontaneous Notification; Abstract; DEFICIENCIES OF PRE-MARKETING TESTS; PRESCRIBING CONDITIONS; ADR REGISTERS IN PMS; ADVANTAGES AND DISADVANTAGES; SPONTANEOUS REPORTING AND IDENTIFICATION OF A NEW HAZARD; RELATIVE RISKS OF VARIOUS DRUGS; ADR'S AND IN-DEPTH STUDIES; WHEN AND WHAT TO REPORT; FEEDBACK OF INFORMATION; CONCLUDING REMARKS; REFERENCES.
  note: editors, Michel Auriche, John Burke, Jacques Duchier.
  note: "Paris, 27/30 April 1981."
  note: "The 4th International Meeting of Pharmaceutical Physicians."--Page vii
  subject:
    topic: Drugs
    genre: Congresses
  subject:
    topic: Drugs
    topic: Side effects
    genre: Congresses
  subject:
    topic: Pharmaceutical Preparations
    topic: standards
  subject:
    topic: Drug Evaluation
  subject:
    topic: Médicaments
    genre: Congrès
  subject:
    topic: Médicaments
    topic: Effets secondaires
    genre: Congrès
  subject:
    topic: MEDICAL
    topic: Pharmacology
  subject:
    topic: Drugs
  subject:
    topic: Drugs
    topic: Side effects
  classification: RS189 .I523 1981eb
  classification: 615.1
  classification: QV771 In82p 1981
  related item:
    title info:
      title: Drug safety
    name:
      name part: International Congress of Pharmaceutical Physicians (4th : 1981 : Paris, France).
    identifier: (OCoLC)10444955
  identifier: 9781483140377
  identifier: 1483140377
  identifier: 9780080270746
  identifier: http://proxy.library.tamu.edu/login
  record info:
    record content source: OPELS
    record creation date: 140723
    record change date: 20260326205931.8
    record identifier: in00005755785
    language of cataloging:
      language term: eng